These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28158844)

  • 1. Association of Neuropathological Markers in the Parietal Cortex With Antemortem Cognitive Function in Persons With Mild Cognitive Impairment and Alzheimer Disease.
    Tremblay C; François A; Delay C; Freland L; Vandal M; Bennett DA; Calon F
    J Neuropathol Exp Neurol; 2017 Feb; 76(2):70-88. PubMed ID: 28158844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Cortical β-Amyloid Protein in the Absence of Insoluble Deposits With Alzheimer Disease.
    Yu L; Petyuk VA; Tasaki S; Boyle PA; Gaiteri C; Schneider JA; De Jager PL; Bennett DA
    JAMA Neurol; 2019 Jul; 76(7):818-826. PubMed ID: 31009033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mild cognitive impairment and asymptomatic Alzheimer disease subjects: equivalent β-amyloid and tau loads with divergent cognitive outcomes.
    Iacono D; Resnick SM; O'Brien R; Zonderman AB; An Y; Pletnikova O; Rudow G; Crain B; Troncoso JC
    J Neuropathol Exp Neurol; 2014 Apr; 73(4):295-304. PubMed ID: 24607960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain mural cell loss in the parietal cortex in Alzheimer's disease correlates with cognitive decline and TDP-43 pathology.
    Bourassa P; Tremblay C; Schneider JA; Bennett DA; Calon F
    Neuropathol Appl Neurobiol; 2020 Aug; 46(5):458-477. PubMed ID: 31970820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global neuropathologic severity of Alzheimer's disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels.
    Murray ME; Moloney CM; Kouri N; Syrjanen JA; Matchett BJ; Rothberg DM; Tranovich JF; Sirmans TNH; Wiste HJ; Boon BDC; Nguyen AT; Reichard RR; Dickson DW; Lowe VJ; Dage JL; Petersen RC; Jack CR; Knopman DS; Vemuri P; Graff-Radford J; Mielke MM
    Mol Neurodegener; 2022 Dec; 17(1):85. PubMed ID: 36575455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in the detergent-insoluble brain proteome linked to amyloid and tau in Alzheimer's Disease progression.
    Hales CM; Dammer EB; Deng Q; Duong DM; Gearing M; Troncoso JC; Thambisetty M; Lah JJ; Shulman JM; Levey AI; Seyfried NT
    Proteomics; 2016 Dec; 16(23):3042-3053. PubMed ID: 27718298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Artificial intelligence-derived neurofibrillary tangle burden is associated with antemortem cognitive impairment.
    Marx GA; Koenigsberg DG; McKenzie AT; Kauffman J; Hanson RW; Whitney K; Signaevsky M; Prastawa M; Iida MA; White CL; Walker JM; Richardson TE; Koll J; Fernandez G; Zeineh J; Cordon-Cardo C; Crary JF; Farrell K;
    Acta Neuropathol Commun; 2022 Oct; 10(1):157. PubMed ID: 36316708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD.
    Tramutola A; Triplett JC; Di Domenico F; Niedowicz DM; Murphy MP; Coccia R; Perluigi M; Butterfield DA
    J Neurochem; 2015 Jun; 133(5):739-49. PubMed ID: 25645581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease.
    Tremblay C; Pilote M; Phivilay A; Emond V; Bennett DA; Calon F
    J Alzheimers Dis; 2007 Dec; 12(4):377-90. PubMed ID: 18198424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria.
    Nagy Z; Esiri MM; Jobst KA; Morris JH; King EM; McDonald B; Litchfield S; Smith A; Barnetson L; Smith AD
    Dementia; 1995; 6(1):21-31. PubMed ID: 7728216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment.
    Newton P; Tchounguen J; Pettigrew C; Lim C; Lin Z; Lu H; Moghekar A; Albert M; Soldan A;
    J Alzheimers Dis; 2023; 92(1):323-339. PubMed ID: 36744337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
    Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
    JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET.
    Devous MD; Fleisher AS; Pontecorvo MJ; Lu M; Siderowf A; Navitsky M; Kennedy I; Southekal S; Harris TS; Mintun MA
    J Alzheimers Dis; 2021; 80(3):1091-1104. PubMed ID: 33682705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of cognitive impairment in primary age-related tauopathy: an autopsy study.
    Iida MA; Farrell K; Walker JM; Richardson TE; Marx GA; Bryce CH; Purohit D; Ayalon G; Beach TG; Bigio EH; Cortes EP; Gearing M; Haroutunian V; McMillan CT; Lee EB; Dickson DW; McKee AC; Stein TD; Trojanowski JQ; Woltjer RL; Kovacs GG; Kofler JK; Kaye J; White CL; Crary JF
    Acta Neuropathol Commun; 2021 Aug; 9(1):134. PubMed ID: 34353357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.
    Petrie EC; Cross DJ; Galasko D; Schellenberg GD; Raskind MA; Peskind ER; Minoshima S
    Arch Neurol; 2009 May; 66(5):632-7. PubMed ID: 19433663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration.
    Irwin DJ; Lleó A; Xie SX; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
    Ann Neurol; 2017 Aug; 82(2):247-258. PubMed ID: 28719018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Plasma Amyloid and Tau in a Longitudinal Study of Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
    Chen TB; Lai YH; Ke TL; Chen JP; Lee YJ; Lin SY; Lin PC; Wang PN; Cheng IH
    Dement Geriatr Cogn Disord; 2019; 48(3-4):180-195. PubMed ID: 31991443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease.
    Ossenkoppele R; Smith R; Ohlsson T; Strandberg O; Mattsson N; Insel PS; Palmqvist S; Hansson O
    Neurology; 2019 Feb; 92(6):e601-e612. PubMed ID: 30626656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.